Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00490516 | ACP-104 in Acutely Psychotic Subjects With Schizophrenia | PHASE2 | COMPLETED | 247 | — | — | Jun 1, 2007 | Feb 1, 2008 | Jan 20, 2025 | 21 | United States |
| NCT00628420 | Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics | PHASE1 | COMPLETED | 45 | — | — | Jan 1, 2005 | Oct 1, 2007 | Jun 28, 2011 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ACP-104 | DRUG | 200 mg, tablet, BID, 6 weeks |
| Placebo | DRUG | placebo, tablet BID, 6 weeks |
Inclusion Criteria: * Male or female; 18-60 years of age * The subject is physically healthy and medically stable. * The subject is able to provide informed consent * The subject has been diagnosed with schizophrenia for at least 1 year * Currently experiencing an acute episode of psychosis * The s...